Focusing on the upcoming EU Health Technology Assessment (HTA) process, this guide provides essential insights for pharmaceutical developers. With the regulation taking effect in 2025, it emphasizes the significance of joint clinical assessments and scientific consultations at the European level. Although market access, pricing, and reimbursement remain under the jurisdiction of individual EU member states, the book highlights how the EU HTA will influence these national activities, equipping stakeholders with the necessary tools to navigate the changes.
